Simultaneous protein expression and modification: an efficient approach for production of unphosphorylated and biotinylated receptor tyrosine kinases by triple infection in the baculovirus expression system.

Protein kinases can adopt multiple protein conformations depending on their activation status. Recently, in drug discovery, a paradigm shift has been initiated, moving from inhibition of fully activated, phosphorylated kinases to targeting the inactive, unphosphorylated forms. For identification and characterization of putative inhibitors, also interacting with the latent kinase conformation outside of the kinase domain, highly purified and homogeneous protein preparations of unphosphorylated kinases are essential. The kinetic parameters of nonphosphorylated kinases cannot be assessed easily by standard kinase enzyme assays as a result of their intrinsic autophosphorylation activity. Kinetic binding rate constants of inhibitor-protein interactions can be measured by biophysical means upon protein immobilization on chips. Protein immobilization can be achieved under mild conditions by binding biotinylated proteins to streptavidin-coated chips, exploiting the strong and highly specific streptavidin-biotin interaction. In the work reported here, the cytoplasmic domains of insulin receptor and insulin-like growth factor-1 receptor fused to a biotin ligase recognition sequence were coexpressed individually with the phosphatase YopH and the biotin-protein ligase BirA upon triple infection in insect cells. Tandem affinity purification yielded pure cytoplasmic kinase domains as judged by gel electrophoresis and HPLC. Liquid chromatography-mass spectrometry analysis showed the absence of any protein phosphorylation. Coexpression of BirA led to quantitative and site-specific biotinylation of the kinases, which had no influence on the catalytic activity of the kinases, as demonstrated by the identical phosphorylation pattern upon autoactivation and by enzymatic assay. This coexpression approach should be applicable to other protein kinases as well and should greatly facilitate the production of protein kinases in their phosphorylated and unphosphorylated state suitable for enzymatic and biophysical studies.

[1]  M. Geiser,et al.  Chaperone over-expression in Escherichia coli: apparent increased yields of soluble recombinant protein kinases are due mainly to soluble aggregates. , 2009, Protein expression and purification.

[2]  Leyu Wang,et al.  High yield expression of non-phosphorylated protein tyrosine kinases in insect cells. , 2008, Protein expression and purification.

[3]  P. Chène Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases. , 2008, Drug discovery today.

[4]  D. Fairlie,et al.  A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. , 2007, Drug discovery today.

[5]  D. M. Penny,et al.  Mouse Aurora A: expression in Escherichia coli and purification. , 2007, Protein expression and purification.

[6]  Catherine K. Smith,et al.  Expression and purification of phosphorylated and non-phosphorylated human MEK1. , 2007, Protein expression and purification.

[7]  D. Wasilko,et al.  TIPS: Titerless Infected-Cells Preservation and Scale-Up , 2006 .

[8]  J. Mestan,et al.  Allosteric inhibitors of Bcr-abl–dependent cell proliferation , 2006, Nature chemical biology.

[9]  J. Kuriyan,et al.  High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases , 2005, Protein science : a publication of the Protein Society.

[10]  P. Lemotte,et al.  Phosphorylation of serine residues in histidine-tag sequences attached to recombinant protein kinases: a cause of heterogeneity in mass and complications in function. , 2005, Protein expression and purification.

[11]  T. Mohanakumar,et al.  In vivo biotinylation of the major histocompatibility complex (MHC) class II/peptide complex by coexpression of BirA enzyme for the generation of MHC class II/tetramers. , 2004, Human immunology.

[12]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[13]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[14]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[15]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[16]  Stevan R. Hubbard,et al.  Structure and autoregulation of the insulin-like growth factor 1 receptor kinase , 2001, Nature Structural Biology.

[17]  H. Nielsen,et al.  Loss of ELISA specificity due to biotinylation of monoclonal antibodies. , 2000, Journal of immunological methods.

[18]  A. Chapman-Smith,et al.  In vivo enzymatic protein biotinylation. , 1999, Biomolecular engineering.

[19]  A. Chapman-Smith,et al.  The enzymatic biotinylation of proteins: a post-translational modification of exceptional specificity. , 1999, Trends in biochemical sciences.

[20]  J. Mccoy,et al.  A plasmid expression system for quantitative in vivo biotinylation of thioredoxin fusion proteins in Escherichia coli. , 1998, Nucleic acids research.

[21]  G. Kulik,et al.  Src Phosphorylates the Insulin-like Growth Factor Type I Receptor on the Autophosphorylation Sites , 1996, The Journal of Biological Chemistry.

[22]  T. Zor,et al.  Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. , 1996, Analytical biochemistry.

[23]  C. S. Zong,et al.  Effect of Tyrosine Mutations on the Kinase Activity and Transforming Potential of an Oncogenic Human Insulin-like Growth Factor I Receptor (*) , 1996, The Journal of Biological Chemistry.

[24]  C. Kahn,et al.  A mutant insulin receptor induces formation of a Shc-growth factor receptor bound protein 2 (Grb2) complex and p21ras-GTP without detectable interaction of insulin receptor substrate 1 (IRS1) with Grb2. Evidence for IRS1-independent p21ras-GTP formation. , 1994, The Journal of biological chemistry.

[25]  C. Kahn,et al.  The insulin signaling system. , 1994, The Journal of biological chemistry.

[26]  P. Schatz Use of Peptide Libraries to Map the Substrate Specificity of a Peptide-Modifying Enzyme: A 13 Residue Consensus Peptide Specifies Biotinylation in Escherichia coli , 1993, Bio/Technology.

[27]  J. C. Clemens,et al.  The Yersinia tyrosine phosphatase: specificity of a bacterial virulence determinant for phosphoproteins in the J774A.1 macrophage , 1992, The Journal of experimental medicine.

[28]  J. C. Clemens,et al.  Expression, purification, and physicochemical characterization of a recombinant Yersinia protein tyrosine phosphatase. , 1992, The Journal of biological chemistry.

[29]  J. Dixon,et al.  Protein tyrosine phosphatase activity of an essential virulence determinant in Yersinia. , 1990, Science.

[30]  J. Cronan Biotination of proteins in vivo. A post-translational modification to label, purify, and study proteins. , 1990, The Journal of biological chemistry.

[31]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[32]  Jeffrey Jie-Lou Liao,et al.  Targeting protein multiple conformations: a structure-based strategy for kinase drug design. , 2007, Current topics in medicinal chemistry.

[33]  Ville Santala,et al.  Production of a biotinylated single-chain antibody fragment in the cytoplasm of Escherichia coli. , 2004, Journal of immunological methods.